Acronis’ Rares Matei Recognized on CRN’s 100 People You Don’t Know But Should for 2023 List 25-09-2023, 21:00

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Shaping Teachers Minds to Shape Students Minds: How the 9-03-2023, 03:52